Triazole-fused pyrimidines in target-based anticancer drug discovery
Xing-Jie Dai
1, 2
,
Lei-Peng Xue
1, 2
,
Shi-Kun Ji
1, 2
,
Ying Zhou
1, 2
,
Ya Gao
1, 2
,
Yichao Zheng
1, 2
,
Huimin Liang
1, 2
,
Hong-Min Liu
1, 2
1
Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China
|
Publication type: Journal Article
Publication date: 2023-03-01
scimago Q1
wos Q1
SJR: 1.142
CiteScore: 11.3
Impact factor: 5.9
ISSN: 02235234, 17683254
PubMed ID:
36724635
Organic Chemistry
Drug Discovery
General Medicine
Pharmacology
Abstract
In recent decades, the development of targeted drugs has featured prominently in the treatment of cancer, which is among the major causes of mortality globally. Triazole-fused pyrimidines, a widely-used class of heterocycles in medicinal chemistry, have attracted considerable interest as potential anticancer agents that target various cancer-associated targets in recent years, demonstrating them as valuable templates for discovering novel anticancer candidates. The current review concentrates on the latest advancements of triazole-pyrimidines as target-based anticancer agents, including works published between 2007 and the present (2007-2022). The structure-activity relationships (SARs) and multiple pathways are also reviewed to shed light on the development of more effective and biotargeted anticancer candidates.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
6
7
|
|
|
Journal of Molecular Structure
7 publications, 16.28%
|
|
|
Journal of Organic Chemistry
3 publications, 6.98%
|
|
|
Molecules
2 publications, 4.65%
|
|
|
European Journal of Organic Chemistry
2 publications, 4.65%
|
|
|
Organic Letters
2 publications, 4.65%
|
|
|
ChemistrySelect
2 publications, 4.65%
|
|
|
RSC Advances
2 publications, 4.65%
|
|
|
European Journal of Medicinal Chemistry
2 publications, 4.65%
|
|
|
Chemical Papers
1 publication, 2.33%
|
|
|
Antioxidants
1 publication, 2.33%
|
|
|
Molecular Simulation
1 publication, 2.33%
|
|
|
Journal of Enzyme Inhibition and Medicinal Chemistry
1 publication, 2.33%
|
|
|
Archives of Biochemistry and Biophysics
1 publication, 2.33%
|
|
|
Pharmacology and Therapeutics
1 publication, 2.33%
|
|
|
International Journal of Molecular Sciences
1 publication, 2.33%
|
|
|
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy
1 publication, 2.33%
|
|
|
ACS applied materials & interfaces
1 publication, 2.33%
|
|
|
Molecular Diversity
1 publication, 2.33%
|
|
|
Biomedicine and Pharmacotherapy
1 publication, 2.33%
|
|
|
Russian Journal of Organic Chemistry
1 publication, 2.33%
|
|
|
Progress in Heterocyclic Chemistry
1 publication, 2.33%
|
|
|
Current Pharmaceutical Design
1 publication, 2.33%
|
|
|
Journal of Chemical Physics
1 publication, 2.33%
|
|
|
Russian Chemical Reviews
1 publication, 2.33%
|
|
|
Polycyclic Aromatic Compounds
1 publication, 2.33%
|
|
|
New Journal of Chemistry
1 publication, 2.33%
|
|
|
Bioorganic Chemistry
1 publication, 2.33%
|
|
|
Anti-Cancer Agents in Medicinal Chemistry
1 publication, 2.33%
|
|
|
Pamukkale University Journal of Engineering Sciences
1 publication, 2.33%
|
|
|
1
2
3
4
5
6
7
|
Publishers
|
2
4
6
8
10
12
14
16
|
|
|
Elsevier
15 publications, 34.88%
|
|
|
American Chemical Society (ACS)
6 publications, 13.95%
|
|
|
MDPI
4 publications, 9.3%
|
|
|
Wiley
4 publications, 9.3%
|
|
|
Taylor & Francis
3 publications, 6.98%
|
|
|
Royal Society of Chemistry (RSC)
3 publications, 6.98%
|
|
|
Springer Nature
2 publications, 4.65%
|
|
|
Bentham Science Publishers Ltd.
2 publications, 4.65%
|
|
|
Pleiades Publishing
1 publication, 2.33%
|
|
|
AIP Publishing
1 publication, 2.33%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 2.33%
|
|
|
Pamukkale University
1 publication, 2.33%
|
|
|
2
4
6
8
10
12
14
16
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
43
Total citations:
43
Citations from 2024:
34
(79.07%)
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Dai X. et al. Triazole-fused pyrimidines in target-based anticancer drug discovery // European Journal of Medicinal Chemistry. 2023. Vol. 249. p. 115101.
GOST all authors (up to 50)
Copy
Dai X., Xue L., Ji S., Zhou Y., Gao Ya., Zheng Y., Liang H., Liu H. Triazole-fused pyrimidines in target-based anticancer drug discovery // European Journal of Medicinal Chemistry. 2023. Vol. 249. p. 115101.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.ejmech.2023.115101
UR - https://doi.org/10.1016/j.ejmech.2023.115101
TI - Triazole-fused pyrimidines in target-based anticancer drug discovery
T2 - European Journal of Medicinal Chemistry
AU - Dai, Xing-Jie
AU - Xue, Lei-Peng
AU - Ji, Shi-Kun
AU - Zhou, Ying
AU - Gao, Ya
AU - Zheng, Yichao
AU - Liang, Huimin
AU - Liu, Hong-Min
PY - 2023
DA - 2023/03/01
PB - Elsevier
SP - 115101
VL - 249
PMID - 36724635
SN - 0223-5234
SN - 1768-3254
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2023_Dai,
author = {Xing-Jie Dai and Lei-Peng Xue and Shi-Kun Ji and Ying Zhou and Ya Gao and Yichao Zheng and Huimin Liang and Hong-Min Liu},
title = {Triazole-fused pyrimidines in target-based anticancer drug discovery},
journal = {European Journal of Medicinal Chemistry},
year = {2023},
volume = {249},
publisher = {Elsevier},
month = {mar},
url = {https://doi.org/10.1016/j.ejmech.2023.115101},
pages = {115101},
doi = {10.1016/j.ejmech.2023.115101}
}